Market Overview

UPDATE: Credit Suisse Initiates Sunesis Pharmaceuticals at Outperform Ahead of Phase II Data

Share:

Credit Suisse initiated coverage on Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) with an Outperform rating and a $7.00 price target.

Credit Suisse commented, "SNSS is a binary risk stock for which upside potential and probability of success are not fully reflected in the current share price. In part, we believe this is because the Phase III read out for vosaroxin is not expected until early 2014. However, we believe that shares could move significantly higher ahead of the event. Investors with binary risk tolerance should consider owning SNSS through the VALOR results. SNSS owns global rights to vosaroxin (owes a midteen royalty), so positive results would put SNSS on a path to commercial profitability or a potential premium acquisition."

Sunesis Pharmaceuticals closed at $4.00 on Monday.

Latest Ratings for SNSS

DateFirmActionFromTo
Dec 2018Initiates Coverage OnNeutral
Dec 2017UpgradesMarket PerformOutperform
Dec 2017DowngradesOutperformMarket Perform

View More Analyst Ratings for SNSS
View the Latest Analyst Ratings

Posted-In: Credit SuisseAnalyst Color Initiation Intraday Update Analyst Ratings

 

Related Articles (SNSS)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
EGBNDowngrades
EBAYMaintains37.0
EBAYMaintains40.0
SQAssumes78.0
PYPLAssumes140.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

UPDATE: Credit Suisse Upgrades Boston Scientific to Outperform on Improving Top-Line

Perrigo Launches betamethason valerate foam 0.12% Commercially